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Abstract
Background: Laboratory tests for routine drug of abuse and toxicology (DOA/Tox) screening,
often used in emergency medicine, generally utilize antibody-based tests (immunoassays) to detect
classes of drugs such as amphetamines, barbiturates, benzodiazepines, opiates, and tricyclic
antidepressants, or individual drugs such as cocaine, methadone, and phencyclidine. A key factor in
assay sensitivity and specificity is the drugs or drug metabolites that were used as antigenic targets
to generate the assay antibodies. All DOA/Tox screening immunoassays can be limited by false
positives caused by cross-reactivity from structurally related compounds. For immunoassays
targeted at a particular class of drugs, there can also be false negatives if there is failure to detect
some drugs or their metabolites within that class.
Methods: Molecular similarity analysis, a computational method commonly used in drug discovery,
was used to calculate structural similarity of a wide range of clinically relevant compounds
(prescription and over-the-counter medications, illicit drugs, and clinically significant metabolites)
to the target ('antigenic') molecules of DOA/Tox screening tests. These results were compared
with cross-reactivity data in the package inserts of immunoassays marketed for clinical testing. The
causes for false positives for phencyclidine and tricyclic antidepressant screening immunoassays
were investigated at the authors' medical center using gas chromatography/mass spectrometry as
a confirmatory method.
Results:  The results illustrate three major challenges for routine DOA/Tox screening
immunoassays used in emergency medicine. First, for some classes of drugs, the structural diversity
of common drugs within each class has been increasing, thereby making it difficult for a single assay
to detect all compounds without compromising specificity. Second, for some screening assays,
common 'out-of-class' drugs may be structurally similar to the target compound so that they
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account for a high frequency of false positives. Illustrating this point, at the authors' medical center,
the majority of positive screening results for phencyclidine and tricyclic antidepressants assays
were explained by out-of-class drugs. Third, different manufacturers have adopted varying
approaches to marketed immunoassays, leading to substantial inter-assay variability.
Conclusion: The expanding structural diversity of drugs presents a difficult challenge for routine
DOA/Tox screening that limit the clinical utility of these tests in the emergency medicine setting.
Background
Medical complications related to drugs account for a sig-
nificant fraction of patient visits to the emergency depart-
ment (ED). These visits may be a result of illicit drug
abuse, intentional or inadvertent overdose of prescription
or over-the-counter medications, or drug-drug interac-
tions [1-3]. There is increasing concern about the danger
posed by misuse of prescription medications, particularly
those with high potential abuse liability (e.g., opioids),
especially when used in combination with ethanol or
street drugs [4]. In some patients, such as those with
altered mental status, a medical history may be unclear at
the time of presentation to the ED. To aid in the diagnosis
and management of drug-related complications, labora-
tory tests to screen for the presence of drugs and drug
metabolites are widely used in emergency medicine [3,5].
We will refer to these tests as 'drug of abuse/toxicology
(DOA/Tox) screening tests'.
Over the last four decades, a number of methods have
been used for DOA/Tox screening including antibody-
based assays (immunoassays) [6,7]. DOA/Tox immu-
noassay screens for amphetamines, barbiturates, benzodi-
azepines, cannabinoids, methadone, opiates, and tricyclic
antidepressants (TCAs) were first introduced into clinical
practice in the United States in the 1970s, initially as radi-
oimmunoassays and later as non-radioactive immu-
noassays [8,9]. Immunoassays have steadily displaced
other DOA/Tox screening methods such as thin-layer
chromatography or colorimetric assays [7]. Currently, the
most common methods used in the United States for
DOA/Tox screening are homogeneous immunoassays
that can be performed rapidly on a variety of different
instruments, ranging from small devices that can be
located within or near the ED to large, high-throughput
analyzers found in hospital clinical laboratories or off-site
reference laboratories [6,7]. Screening assays are different
from confirmatory tests such as gas chromatography/mass
spectrometry (GC/MS) that can provide definitive identi-
fication of individual drugs and their metabolites [7].
Confirmatory tests are often more labor-intensive, techni-
cally demanding, and expensive compared with screening
tests. For many EDs, confirmatory tests are available only
by referral of patient samples to an off-site reference labo-
ratory, such that turnaround time for results is often not
fast enough to aid in real-time patient management.
In the United States, there are currently marketed DOA/
Tox screening immunoassays for 18 targets (i.e., single
drugs or drug classes) including: amphetamines, barbitu-
rates, benzodiazepines, cocaine metabolite/benzoylecgo-
nine, buprenorphine, cannabinoids, heroin metabolite/6-
acetylmorphine (6-AM), lysergic acid diethylamide
(LSD), MDMA/Ecstasy (3,4-methylenedioxymetham-
phetamine), methadone, methadone metabolite/EDDP
(2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine),
methaqualone, nicotine metabolite/cotinine, opiates,
oxycodone, phencyclidine (PCP), propoxyphene, and
TCAs. For some drugs or metabolites (e.g., buprenor-
phine, heroin metabolite/6-AM), there may be only one
or two manufacturers marketing an assay whereas for
more common tests (e.g., amphetamines, benzodi-
azepines, opiates), there are many different marketed
assays. Different assays for the same analyte may vary in
terms of analytical sensitivity and specificity, leading to
potential difficulties in clinical interpretation. DOA/Tox
screening test is most often performed on urine but, in
some cases, serum/plasma or saliva may be used [5,7,10].
DOA/Tox screening immunoassays may be designed by
raising antibodies against a single drug or drug metabolite
('target compound'). Alternatively, multiple target com-
pounds may be used to achieve broader detection of a
class of drugs. There is a general trend towards use of mon-
oclonal antibodies in marketed assays, but assays using
polyclonal antibodies are still used widely in some cases
[6,7]. Theoretically, use of monoclonal antibodies pro-
vides more consistent performance over polyclonal anti-
bodies. DOA/Tox screening assays may be directed at
classes of drugs such as amphetamines, barbiturates, ben-
zodiazepines, cannabinoids, and opiates [7,10]. In these
'broad specificity' DOA/Tox assays, ideally the specificity
of the assay is broad enough to detect a range of 'within-
class' compounds but not too non-specific to cross-react
with 'out-of-class' compounds that may have similar
chemical structures. Other DOA/Tox screening assays are
directed towards detection of a single target compound
(drug or drug metabolite) without cross-reactivity withBMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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other similar structures. Examples of 'single target' DOA/
Tox assays include those for buprenorphine, methadone,
and propoxyphene.
DOA/Tox screening immunoassays have two main limita-
tions. First, false positives may occur when an 'out-of-
class' compound with structural similarity to the target
compound(s) causes a positive screening result [3,5,6,10].
Such cross-reactive molecules can be structurally related
drugs, drug metabolites, or endogenous compounds
[7,11]. Manufacturers of DOA/Tox screening immu-
noassays typically test commonly used drugs for cross-
reactivity including over-the-counter and prescription
medications likely to be taken concomitantly with the tar-
get drug, as well as various other compounds [12]. Infor-
mation on assay sensitivity and cross-reactivity is
normally reported in the package insert of the assay or the
website of the manufacturer. In other cases, cross-reacting
compounds for DOA/Tox screening assays are not
reported by the assay manufacturer in the package insert
but instead are first described in the medical literature.
Examples of such published reports of DOA/Tox assay
cross-reactivity include fluoroquinolone antibiotic cross-
reactivity with opiate assays [13], venlafaxine cross-reac-
tivity with PCP immunoassays [14-16], and quetiapine
cross-reactivity with TCA assays [17-19]. The second main
limitation of DOA/Tox screening immunaossays is failure
to detect some drugs within a class, resulting in false neg-
atives [3,5,6,10]. Examples of false negatives would be
inability to detect clonazepam in a benzodiazepines assay
or oxycodone in an opiates assay. Some examples of drugs
that can cause false negatives and false positives in DOA/
Tox immunoassays are listed in Tables 1 and 2.
In clinical practice, drugs are commonly classified by their
therapeutic class, but this does not explicitly define how
similar drugs may be to one another in terms of chemical
structure and their potential for cross-reactivity in DOA/
Tox screening immunoassays. Therefore, we have utilized
a computational method known as similarity analysis
between molecules [20,21]. Variables that can be
included in similarity calculations are extensive and
include those related to molecular structure, electrostatic
potential, shape, and electron density. Similarity analysis
has been used widely in the pharmaceutical industry as a
'virtual' screen for identifying drug-like molecules and
predicting drug toxicity, and can be valuable in narrowing
the number of compounds subjected to in vitro, animal, or
Table 1: Drugs or drug metabolites that can produce false negatives on DOA/Tox screening immunoassays
Cross-Reactivity to Marketed Immunoassays
Drug Assay1 Similarity to assay 
target compound2
Abbott3 Beckman3 Biosite Triage3 Microgenics3 Roche3 Siemens3
MDMA AMPH 0.361 1,300 2,500 2,000 1,300 697,000 34,300
Alprazolam BENZO 0.610 113 300 450 25 219 65
Clonazepam BENZO 0.656 214 300 350 3,000 307 260
Clonazepam 
metabolite (7-amino)
BENZO 0.755 2,334 800 7,500 1,000 288 5,700
Clobazam BENZO 0.796 218 500 700 250 237 260
Buprenorphine OPIA 0.783 No effect No effect
Oxycodone OPIA 0.800 No effect 17,000 20,000 16,000 > 75,000 2,550
Oxymorphone OPIA 0.847 No effect No effect 40,000 40,000 > 20,000
Amoxapine TCA 0.508 No effect No effect No effect No effect
1 Assay abbreviations: AMPH, amphetamines; BENZO, benzodiazepines; OPIA, opiates; TCA, tricyclic antidepressants.
2 Target compounds: AMPH, d-amphetamine; BENZO, diazepam; OPIA, morphine; TCA, desipramine. Similarity calculated using MDL public keys 
with Tanimoto coefficient.
3 Concentration of compound in ng/mL that produces cross-reactivity equal to 1,000 d-amphetamine (AMPH assay), 200 ng/mL diazepam (BENZO 
assay), 300 ng/mL morphine (OPIA assay), or 1,000 ng/mL desipramine (TCA assay). Blank cells indicate that no cross-reactivity data is reported. 
For all assays except TCA, marketed assays are for Abbott Architect, Beckman, Biosite Triage, Microgenics DRI, Roche cobas c, and Siemens Syva 
EMIT systems. For TCA, marketed assays are Abbott AxSYM, Biosite Triage, Microgenics DRI serum, and Siemens Syva EMIT systems. See 
Additional file 1 (tab T) for more details.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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human testing [20,22,23]. In our analysis, we have used
two-dimensional (2D) similarity with the Tanimoto coef-
ficient, which compares two compounds and generates a
similarity measure that ranges from 0 to 1, with 0 being
maximally dissimilar and 1 being maximally similar
[21,24]. We have found that this similarity measure corre-
lates well with cross-reactivity of immunoassays used clin-
ically for DOA/Tox screening and therapeutic drug
monitoring [25,26].
In this study, we applied similarity analysis as a quantita-
tive tool to rationalize false positives and false negatives of
DOA/Tox screening assays. We have also compiled histor-
ical data on prescription drug usage in the United States to
demonstrate how changing patterns of drug use may
influence clinical utility of DOA/Tox screening assays.
Lastly, we present the results of our own investigation into
the causes for positive screening results for PCP and TCA
screening assays in our medical center, which has adult
and pediatric EDs that serve as a regional toxicology refer-
ral center.
Methods
Similarity Calculations
Similarity searching uses the 'find similar molecules by
fingerprints' protocol in the library analysis module of
Discovery Studio 2.0 (Accelrys, San Diego, CA). The MDL
public keys are a fingerprint which uses a pre-defined set
of definitions related to structural features [27]. A finger-
print is created based on pattern matching of the structure
to this set of 166 keys. These MDL keys are used separately
with the Tanimoto similarity coefficient and an input
query molecule [21] and will be referred to as 'Tanimoto
similarity'. It should be noted that this type of similarity
algorithm does not recognize differences between stereoi-
somers (e.g., d- and l-amphetamine or their racemic mix-
ture; citalopram and escitalopram). Sdf files of the
structures of the database compounds are available on
request from the authors.
Cross-Reactivity Testing and Confirmatory Testing
Quetiapine fumarate was obtained from Sequoia
Research Products (Pangbourne, United Kingdom).
Quetiapine S-oxide, 7-hydroxyquetiapine, and 11-piper-
azin-1yl-dibenzo [b, f] [1, 4] thiazepine dihydrochloride
(DBTP) were purchased from Molcan (Toronto, Ontario,
Canada). These three quetiapine metabolites were tested
for cross-reactivity with two different TCA screening
immunoassays: (1) Emit® tox™ serum (tricyclic antidepres-
sants) run on Siemens (Dade-Behring) Viva-E analyzers
and (2) Biosite Triage® Tox screen. Both assays were per-
formed following manufacturers' instructions on analyz-
Table 2: Drugs that can produce false positives on broad specificity DOA/Tox screening immunoassays
Cross-Reactivity to Marketed Immunoassays
Drug Assay1 Similarity to assay 
target compound2
Abbott3 Beckman3 Biosite Triage3 Microgenics3 Roche3 Siemens3
Phentermine AMPH 0.778 No effect No effect 750,000 No effect 25,000
Levofloxacin OPIA 0.560 1,700,000 No effect 125,000 60,000 200,000
Dextromethorphan PCP 0.565 12,900 No effect 500,000 No effect No effect 12,000
Meperidine PCP 0.538 34,650 No effect No effect No effect No effect 25,000
Carbamazepine TCA 0.460 29,972 No effect No effect No effect
Cyclobenzaprine TCA 0.565 2,000 450
Prochlorperazine TCA 0.630 999 100,000
Quetiapine TCA 0.485 2,484 No effect No effect 100,000
1 Assay abbreviations: AMPH, amphetamines; OPIA, opiates; PCP, phencyclidine; TCA, tricyclic antidepressants.
2 Target compounds: AMPH, d-amphetamine; OPIA, morphine; PCP, phencyclidine; TCA, desipramine. Similarity calculated using MDL public keys 
with Tanimoto coefficient.
3 Concentration of compound in ng/mL that produces cross-reactivity equal to 1,000 d-amphetamine (AMPH assay), 300 ng/mL morphine (OPIA 
assay), 25 ng/mL phencyclidine (PCP assay), or 1,000 ng/mL desipramine (TCA assay). Blank cells indicate that no cross-reactivity data is reported. 
For all assays except TCA, marketed assays are Abbott Architect, Beckman, Biosite Triage, Microgenics DRI, Roche cobas c, Siemens Syva EMIT. 
For TCA, marketed assays are Abbott AxSYM, Biosite Triage, Microgenics DRI serum, and Siemen Syva EMIT. See Additional file 1 (tab T) for more 
detail.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
Page 5 of 18
(page number not for citation purposes)
ers used for clinical testing. Urine samples were analyzed
by GC/MS to identify a wide range of clinically important
drugs and drug metabolites by methods previously
described [28]. Patient samples from five University of
Pittsburgh Medical Center hospitals (Children's, Monte-
fiore, Presbyterian, Shadyside, and Western Psychiatric)
showing positive immunoassay screens for PCP or TCAs
were followed by GC/MS testing. The studies involving
human samples in this report qualified as exempt, and the
need for informed written consent was waived, as deter-
mined by the University of Pittsburgh Medical Center
Institutional Review Board.
Cross-reactivity data
Cross-reactivity data for DOA/Tox immunoassays were
retrieved and compiled from package inserts or the assay
manufacturers' websites. Data for levofloxacin in Table 2
was obtained from a published article [13]. Complete
data for each assay, with compounds sorted and color-
coded by classification, is in Additional file 1 (tabs A-R,
T). The most prescribed medications in the United States
in 2007 [29] is also included in Additional file 1 (tab S).
Information on the most prescribed medications in the
United States from 1970–2006 is provided in Additional
file 2.
Results
Illustration of Molecular Similarity
We have used the MDL public keys, and a molecular sim-
ilarity measure (Tanimoto coefficient), to compute the
structural similarity between drugs and drug metabolites
to the target compounds used in commercially marketed
DOA/Tox immunoassay screens. We have illustrated this
using PCP as an example. Figure 1 shows the similarity of
PCP to 4-phenyl-4-piperidino-cyclohexanol (a PCP
metabolite), dextromethorphan (cause of false positives
on some PCP screening assays), meperidine (another
potential cause of false positives), ketamine, and ibupro-
fen. PCP has the highest Tanimoto similarity (in descend-
ing order) to 4-phenyl-4-piperidino-cyclohexanol
(0.784), dextromethorphan (0.565), and meperidine
(0.538). All three of these compounds are known to cross-
react with some marketed PCP assays, but with varying
sensitivities as reported in the package inserts (Additional
file 1, tab P).
For example, only 30 ng/mL of 4-phenyl-4-piperidino-
cyclohexanol produces cross-reactivity equal to 25 ng/mL
PCP in the Abbott Architect PCP assay. Dextromethor-
phan is reported to cross-react with 4 of 8 commonly mar-
keted PCP assays, with 12,000 ng/mL providing cross-
reactivity equal to 25 ng/mL PCP in the Syva EMIT assay
but with 500,000 ng/mL needed to do the same for the
Biosite Triage assay (Additional file 1, tab P). Meperidine
only cross-reacts with 2 of 8 marketed assays (Abbott
Architect and Syva EMIT). As shown in Figure 1, ketamine,
despite similarity to PCP in terms of mechanism of action
and clinical effects [30], is not that closely related to PCP
structurally as measured by 2D similarity (0.333) and is
also not known to cross-react with marketed PCP assays
(Additional file 1, tab P). PCP has essentially no 2D simi-
larity to ibuprofen (0.100), a widely used drug that does
not cross-react at all with PCP assays (Figure 1).
We will now apply similarity calculation to our analysis
and discussion of individual DOA/Tox screening assays.
Amphetamine Assays
Currently marketed amphetamine screening immu-
noassays in the United States use d-amphetamine,  d-
methamphetamine, or both drugs as the antigenic targets
(Additional file 1, tab T). d-Amphetamine and d-metham-
phetamine have high similarity to one another (Tanimoto
similarity = 0.765) and only 1 currently marketed
amphetamine screening assay (Roche cobas c) has mark-
edly different sensitivities for these two amphetamines
(Figure 2A; Additional file 1, tab A). There is much more
variability in detection by these assays for amphetamine
derivatives such as MDMA/Ecstasy (Tanimoto similarity
to amphetamine = 0.361) and 3,4-methylenedioxyam-
Illustration of structural similarity Figure 1
Illustration of structural similarity. Using phencyclidine 
(PCP) as the target compound, 2D similarity was calculated 
using MDL public keys and the Tanimoto coefficient to five 
different compounds, three of which (dextromethorphan, 
meperidine, and the phencyclidine metabolite 4-phenyl-4-pip-
eridino-cyclohexanol) have been reported to cross-react 
with at least some marketed PCP immunoassays, and two of 
which (ketamine and ibuprofen) have not been reported to 
cross-react with PCP screening assays. PCP has the highest 
similarity (in descending order) to 4-phenyl-4-piperidino-
cyclohexanol, dextromethorphan, and meperidine. PCP has 
low structural similarity to ketamine (despite having similar 
pharmacological properties to PCP) and essentially no struc-
tural similarity to ibuprofen.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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Variability in sensitivity of marketed amphetamine and benzodiazepine screening immunoassays Figure 2
Variability in sensitivity of marketed amphetamine and benzodiazepine screening immunoassays. The plotted 
circles indicate the concentration of compound that produces an equivalent reaction to 1000 ng/mL d-amphetamine (ampheta-
mine assays) or 200 ng/mL diazepam (benzodiazepine assays). The dashed lines bracket clinically or toxicologically relevant 
concentrations from studies in the published literature (see text of Results for detailed description). A) Amphetamine assays. 
With one exception (Roche cobas c assay), marketed amphetamine screening immunoassays detect amphetamine and meth-
amphetamine well but have variable and often low cross-reactivity with MDA, MDMA, MDEA, and phentermine. B) Benzodi-
azepine assays. Marketed benzodiazepine screening immunoassays generally have higher sensitivity to diazepam, oxazepam, and 
nordiazepam than to 7-aminoclonazepam (main clonazepam urinary metabolite) or lorazepam glucuronide (main lorazepam 
urinary metabolite).BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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phetamine (MDA; Tanimoto similarity to amphetamine =
0.424). The low levels of 2D structural similarity of MDA
and MDMA to amphetamine (or methamphetamine) are
comparable or lower than those between amphetamine
and bupropion (Tanimoto similarity = 0.321), ephedrine
(Tanimoto similarity = 0.391), labetalol (Tanimoto simi-
larity = 0.298), mexiletine (Tanimoto similarity = 0.500),
phentermine (Tanimoto similarity = 0.778), and pseu-
doephedrine (Tanimoto similarity = 0.391).
This presents a difficult challenge in developing antibod-
ies broad enough to detect a range of amphetamine deriv-
atives but avoiding widely used drugs with potential for
cross-reactivity such as bupropion, labetalol, or pseu-
doephedrine. Figure 2A shows the cross-reactivities of six
marketed amphetamine assays for d-amphetamine,  d-
methamphetamine, MDA, MDMA, 3,4-methylenediox-
yethylamphetamine (MDEA), and phentermine. As can
be seen, there is wide variability in the ability of these
assays to detect MDA, MDMA, and MDEA (note the ordi-
nate in Figure 2A is on a logarithmic scale). One clinical
consequence of this may be that a patient abusing MDMA
can have opposing test results if evaluated by two different
assay systems (e.g., because of transfer from one hospital
to another). More recently, specific MDMA immu-
noassays that have good cross-reactivity with MDA and
MDEA but essentially no cross-reactivity with d-ampheta-
mine or d-methamphetamine have been developed and
marketed (Additional file 1, tab T).
An additional challenge in interpreting amphetamine
screening assay results is that prescriptions for ampheta-
mine mixed salts (e.g., Adderall®) are now common, rank-
ing #66 in total volume of prescriptions in the United
States in 2007 (Additional file 1, tab S; Table 3). A phar-
macokinetic study of individuals taking Adderall® for at
least 5 consecutive days showed peak urine concentra-
tions (5,739 to 19,172 ng/mL) that greatly exceed the
1,000 ng/mL cutoff often used in screening immu-
noassays, and in general urine amphetamine concentra-
tions that were mostly above 1,000 ng/mL [31].
The plots in Figure 2A include dashed brackets to indicate
clinically or toxicologically relevant urine concentrations
Table 3: Frequency of prescriptions of target compounds and structurally related drugs for DOA/Tox immunoassays
Immunoassay Target compound(s) of 
marketed assays
Highest rank of most 
prescribed in the United 
States during 1970s and 
1980s1
Rank as most 
prescribed in United 
States in 20072
Structurally related top 
prescribed drugs in 2007 
and their rank as most 
prescribed in United 
States2
Amphetamines d-Amphetamine
d-Methamphetamine3
Top 100 (1970–1971)
Top 200 (1970)
66
Unranked
Bupropion (44)
Barbiturates Secobarbital Top 50 (1970–1971) Unranked Butalbital (163)
Phenobarbital (204)
Benzo-diazepines Diazepam
Nordiazepam3
Oxazepam3
1 (1972–1979)
Not applicable
93 (1976)
71
Not applicable
Unranked
Alprazolam (16)
Lorazepam (40)
Clonazepam (45)
Temazepam (111)
Opiates Morphine Top 200 (1970) 230 Hydrocodone (2)
Oxycodone (17)
Codeine (37)
Buprenorphine (248)
Hydromorphone (270)
Tricyclic antidepressants Desipramine
Imipramine
Unranked
82 (1972)
Unranked
268
Cyclobenzaprine (47)
Amitriptyline (70)
Quetiapine (92)
Nortriptyline (194)
Doxepin (236)
Carbamazepine (237)
Prochlorperazine (240)
1 Top prescribed medications in the United States compiled from multiple sources (see Additional file 2).
2 See Additional file 1, tab T.
3 d-Methamphetamine is not prescribed but is widely abused. Nordiazepam is not a prescribed medication but is a metabolite of several 
benzodiazepines (chlordiazepoxide, clorazepate, diazepam, and prazepam). Oxazepam is both a parent drug and potential metabolite of multiple 
benzodiazepines (chlordiazepoxide, clorazepate, diazepam, prazepam, and temazepam). Imipramine is metabolized to desipramine.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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from published studies. For amphetamine and metham-
phetamine, the urinary concentrations indicated by
dashed brackets in Figure 2A are the ranges found in a
pharmacokinetic study involving four consecutive daily
doses of methamphetamine [32]. In this study, the urine
concentrations achieved generally exceeded the 1,000 ng/
mL positive cutoff for both amphetamine and metham-
phetamine. For MDMA and MDA, the range of urine con-
centrations indicated by dashed brackets in Figure 2A are
from 25 antemortem urine concentrations in fatal cases
associated with MDMA overdose [33]. Note that even
these very high MDMA and MDA urine concentrations do
not exceed the threshold for positivity on some ampheta-
mine screening immunoassays. The dashed brackets in
the phentermine plot in Figure 2A are the range of urine
concentrations reported in forensic studies of phenter-
mine overdose [34]. These very high phentermine urine
concentrations would exceed the positive cutoff for only
two marketed amphetamine screening immunoassays.
Consequently, currently marketed amphetamine screen-
ing immunoassays generally do not cross-react with phen-
termine or do so only when this drug is taken in extreme
overdose.
Barbiturate Assays
All currently marketed barbiturate immunoassays use
secobarbital as a target compound, with some containing
antibodies raised only against secobarbital, while others
use antibodies raised against multiple barbiturates (Addi-
tional file 1, tab T). The choice of secobarbital as the anti-
genic target in first-generation barbiturate immunoassays
followed from this intermediate-acting barbiturate being
one of the most heavily prescribed and abused barbitu-
rates of the 1960s and 1970s [35]. Based on similarity cal-
culations, clinically used barbiturates do not possess as
much 'within-class' structural variability as the ampheta-
mines discussed above. Clinically important barbiturates
have MDL similarities of 0.7 or greater to one another and
low structural similarity to other classes of drugs, proba-
bly explaining why barbiturate assays have very few docu-
mented out-of-class cross-reactive compounds
(Additional file 1, tab B). One known cross-reactive drug,
aminoglutethimide (Tanimoto similarity = 0.567 relative
to secobarbital), is not widely used in the United States
and would be an uncommon cause of a barbiturate
screening assay false positive. Prescriptions and abuse of
barbiturates have been declining steadily in the United
States for the past three decades [3]. For example, in the
1970s, six barbiturates were among the most highly pre-
scribed medications in the United States (Additional file
2, figure S2-A). However, other medications such as ben-
zodiazepines, eszopiclone, and zolpidem have steadily
replaced barbiturates as safer hypnotics, anxiolytics, and
sedatives (Additional file 2-figures S2-B,C). Currently,
only two barbiturates (butalbital and phenobarbital) rank
in the top most prescribed medications in the United
States (Additional file 1, tab S and Additional file 2, figure
S2-C) [29].
Benzodiazepine Assays
First-generation benzodiazepine screening assays of the
1970s used one of three antigenic targets [36,37] –
diazepam, nordiazepam, or oxazepam – with a recent
shift towards using multiple benzodiazepines as antigenic
targets (Additional file 1, tab T). The original choice of
diazepam, nordiazepam, or oxazepam also followed from
historical trends in usage of benzodiazepines. Diazepam
was the most prescribed medication overall in the United
States for over a decade (Additional file 2). Other com-
monly prescribed benzodiazepines of the 1970s, includ-
ing chlordiazepoxide and clorazepate, are metabolized to
nordiazepam and oxazepam (Additional file 2, figure S2-
D). Using diazepam, nordiazepam, or oxazepam as target
compounds thus fit the prescribing patterns of the 1970s
well, either by targeting the most commonly prescribed
benzodiazepine of that time (diazepam) or targeting
metabolites common to multiple benzodiazepines.
However, three benzodiazepines (alprazolam, clon-
azepam, and lorazepam) are currently more commonly
prescribed in the United States than diazepam (Addi-
tional file 2, figure S2-C; Table 3) [29]. None of these
three 'newer' benzodiazepines are metabolized to nor-
diazepam or oxazepam; in addition, each has lower simi-
larity to diazepam than does nordiazepam (Tanimoto
similarities to diazepam: nordiazepam, 0.780; lorazepam,
0.673; clonazepam, 0.656; alprazolam, 0.610). The mar-
keted benzodiazepine screening immunoassays therefore
have difficulty in detection of clonazepam and lorazepam
usage, as compared to the use of diazepam or other early
generation benzodiazepines.
Figure 2B plots the cross-reactivities of marketed benzodi-
azepine assays towards diazepam, nordiazepam,
oxazepam, 7-aminoclonazepam, and lorazepam glucuro-
nide (note that cross-reactivity is not reported for all of
these compounds for some of the assays). The upper
brackets for diazepam, nordiazepam, and oxazepam in
Figure 2B indicate the maximum urine concentrations
detected in individual consuming a single diazepam dose
of 10 mg or less [38]. As can be seen, even a single
diazepam dose can result in urine concentration of
diazepam and multiple metabolites that exceed the posi-
tive cutoff for benzodiazepine screening immunoassays
(Figure 2B). Detection would be predicted to be even eas-
ier in patients on chronic therapy, where steady-state
urine concentrations of diazepam and multiple metabo-
lites would accumulate to even higher concentrations.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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Currently marketed benzodiazepine screening assays have
limited sensitivity to detecting use of clonazepam.
Although marketed benzodiazepine assays have reasona-
bly good sensitivity to clonazepam (parent drug), sensitiv-
ity is much lower to the major urinary metabolite 7-
aminoclonazepam (Additional file 1, tab C). Following
oral administration, the majority of clonazepam appears
in the urine as the metabolite 7-aminoclonazepam
[39,40]. In a study of clonazepam pharmacokinetics fol-
lowing a single 3 mg dose [40], the highest peak urine
concentration of 7-aminoclonazepam (~ 183 ng/mL)
recorded in all study participants would still be below the
reported concentrations of 7-aminoclonazepam necessary
to produce a positive screening result in all currently mar-
keted benzodiazepine screening immunoassays (dashed
bracket in Figure 2B; Additional file 1, tab C). Even with
chronic administration of clonazepam, urine concentra-
tions of 7-aminoclonazepam may still be below the posi-
tive cutoff for most benzodiazepine screening
immunoassays in clinical situations.
Currently marketed benzodiazepine screening assays also
have difficulty in detecting the use of lorazepam. Studies
of lorazepam pharmacokinetics following oral or
parenteral administration show that very little unchanged
drug is excreted in the urine, with the majority appearing
as the glucuronide metabolite [41,42]. Lorazepam glu-
curonide has low structural similarity to diazepam (Tani-
moto similarity = 0.561) and is detected much more
poorly by the marketed assays than unconjugated
lorazepam (Additional file 1, tab C). Some marketed ben-
zodiazepine immunoassays can include a separate step to
cleave the glucuronide bonds (e.g., by enzymatic or chem-
ical reaction), resulting in unconjugated drugs. For a drug
such as lorazepam, where the glucuronide metabolite is
the predominant form in the urine, cleaving the glucuro-
nide bonds would be predicted to enhance the detection
rate. Some marketed assays (e.g., Syva EMIT-H® and Roche
Online KIMS®) incorporate a glucuronide cleavage step in
the reaction, while still maintaining rapid analysis times
[43,44].
Cocaine assays
All cocaine screening immunoassays currently marketed
in the United States use antibodies raised against ben-
zoylecognine, one of the two major cocaine metabolites
in humans [7], as the antigenic target (Additional file 1,
tab T). Thus, the marketed assays can be termed more pre-
cisely 'cocaine metabolite screening assays' or 'ben-
zoylecgonine screening assays'. Currently these marketed
assays detect cocaine (parent drug) weakly, with cross-
reactivities equal to 300 ng/mL benzoylecgonine only
occurring at cocaine concentrations ranging from 10,000
ng/mL (Abbott AxSYM) to 80,000 ng/mL (Syva EMIT)
(Additional file 1, tab F; Figure 3A). In clinical practice,
this means that very recent use of cocaine, even in large
amounts, may fail to trigger a positive screen if too little
time has elapsed for the metabolism of the parent drug to
benzoylecgonine to occur. The marketed assays also vary
in detection of other cocaine metabolites such as ecgo-
nine, ecgonine methyl ester (the second major cocaine
metabolite in most individuals) [7], and benzylnorecgo-
nine (Additional file 1, tab F; Figure 3A), potentially lead-
ing to different results if a patient sample is tested on more
than one immunoassay system. The upper brackets for all
compounds in Figure 3A except cocaethylene indicate
peak urine concentrations of cocaine and metabolites fol-
lowing controlled administration of 40 mg cocaine by the
inhalation route [45]. For cocaethylene (an adduct prod-
uct of cocaine and ethanol), the upper bracket indicates
the peak urine concentration in a controlled study of
simultaneous cocaine and ethanol administration [46].
Figure 3A illustrates the low cross-reactivity of marketed
cocaine metabolite immunoassays to all compounds
except benzoylecgonine.
Molecular similarity also explains the generally low false
positive rates for cocaine metabolite assays. In terms of
similarity, benzoylecgonine has low structural similarity
(Tanimoto similarity of 0.615 or lower) to common med-
ications or illicit drugs. Despite being a local anesthetic
(in addition to its other effects), cocaine has low structural
similarity to other clinically important local anesthetics
(e.g., bupivacaine, lidocaine, and procaine), which have
Tanimoto similarities to benzoylecgonine of 0.377 or
lower, effectively explaining why such compounds or
their metabolites do not cause false positives on the cur-
rently available cocaine metabolite screening immu-
noassays (Additional file 1, tab F).
Opiate assays
Unlike barbiturate and benzodiazepine screening immu-
noassays, where some manufacturers have used multiple
drugs or drug metabolites as antigenic targets, all currently
marketed opiate immunoassays use antibodies raised
solely against morphine (Additional file 1, tab T). Based
on our similarity calculations, this strategy would be pre-
dicted to be effective for the sensitive detection of opiates
and metabolites that are structurally very close to mor-
phine, including codeine (Tanimoto similarity to mor-
phine = 0.943), heroin (Tanimoto similarity = 0.857), 6-
AM (main metabolite of heroin; Tanimoto similarity =
0.891), and hydromorphone (Tanimoto similarity =
0.873). In fact, the package insert data reveals this gener-
ally to be true with few exceptions (e.g., a few assays are
less sensitive to hydromorphone than to codeine; Addi-
tional file 1, tab N; Figure 3B). Currently marketed opiate
immunoassays perform less well in their detection of oxy-
codone (Tanimoto similarity to morphine = 0.800) with
2 of 8 marketed assays being essentially insensitive to oxy-BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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Variability in sensitivity of marketed cocaine metabolite and opiate screening immunoassays Figure 3
Variability in sensitivity of marketed cocaine metabolite and opiate screening immunoassays. The plotted circles 
indicate the concentration of compound that produces equivalent reaction to 300 ng/mL benzoylecgonine (cocaine metabolite 
assays) or 300 ng/mL morphine (opiate assays). The dashed lines bracket clinically or toxicologically relevant concentrations 
from studies in the published literature (see text of Results for detailed description). A) Cocaine metabolite assays. Marketed 
cocaine metabolite detect benzoylecgonine with high sensitivity but generally have low sensitivity for detection of cocaine (par-
ent drug) and metabolites other than benzoylecgonine. B) Opiate assays. Marketed opiate assays detect morphine, codeine, 
and hydrocodone well but have variability and often poor sensitivity to oxycodone and oxymorphone.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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codone and 3 additional assays only producing cross-reac-
tivity equal to 300 ng/mL morphine at oxycodone
concentrations of 16,000 ng/mL or greater (Additional
file 1, tab N; Figure 3B; Table 1). These assays also respond
weakly to oxymorphone (Figure 3B), itself a clinically
used drug and also a main metabolite of oxycodone [47].
The lack of sensitivity of marketed opiate assays to oxyco-
done is a serious limitation as this drug is now prescribed
more often in the United States than codeine, morphine,
and propoxyphene (Additional file 2, figure S2-E; Table 3)
and is also a frequently abused prescription medication
[48].
The upper and lower brackets for morphine, codeine,
hydromorphone, hydrocodone, and oxycodone in Figure
3B represent estimated steady-state urine concentrations
in a 70 kg individual during chronic administration of
daily 60 mg oral dose of codeine, 10 mg intramuscular
dose of morphine, 5 mg oral dose of hydromorphone, 10
mg oral dose of hydrocodone, or 20 mg oral dose of oxy-
codone, respectively [49]. As can be seen in Figure 3B, the
steady-state urine concentrations for all drugs except oxy-
codone will generally exceed the cutoff equivalent to 300
ng/mL morphine. For oxycodone, only 3 of 7 marketed
assays have sensitivities to oxycodone sufficient to readily
detect daily use of 20 mg oral oxycodone. Exact urine con-
centrations of oxymorphone following either oxymor-
phone or oxycodone administration have not been
reported in the literature but are likely to be well below
the assay sensitivities due to the extensive metabolism of
oxymorphone prior to renal excretion [50,51]. The upper
bracket for 6-AM is the highest peak 6-AM urine concen-
tration observed in a study of controlled heroin adminis-
tration [52].
Marketed opiate assays do not cross-react with the mixed
opiate agonist-antagonist buprenorphine (Tanimoto sim-
ilarity to morphine = 0.783) (Additional file 1, tab N).
Commonly used non-opiate opioid drugs (e.g., fentanyl,
meperidine, methadone, propoxyphene) generally have
low structural similarity to morphine (Tanimoto similar-
ity range = 0.407 – 0.522) and either do not cross-react, or
do so only at extremely high concentrations, with opiate
screening immunoassays (Additional file 1, tab N).
Phencyclidine assays
As a drug of abuse in the United States, PCP has waxed
and waned in popularity over time, with substantial
regional differences in usage of this drug [53]. There are
five well-documented cross-reactive compounds with PCP
immunoassays: dextromethorphan, venlafaxine [14-16],
meperidine, thioridazine, and mesoridazine (Additional
file 1, tab P), although high urine concentrations of these
drugs are generally required to elicit a positive PCP screen-
ing result (Figure 4A; brackets indicate urine concentra-
tions of PCP in patients abusing PCP [54]). While
prescriptions for the latter three drugs have declined in the
United States over the last decade, venlafaxine is widely
prescribed in the United States (55th most prescribed drug
in 2008) [29], and dextromethorphan continues to be
widely used as both a prescription and over-the-counter
medication in anti-tussive remedies (Table 3) [29]. Supra-
therapeutic doses of dextromethorphan-containing medi-
cations are sometimes abused for psychoactive effects,
most frequently by adolescents and young adults [55].
In our own medical system, we had anecdotally observed
that PCP abuse by patients presenting to our ED was rare,
whereas intentional dextromethorphan and meperidine
usage was more common, suggesting that there may be
many false positive PCP screening tests. We therefore
examined the causes of PCP positive screens in our medi-
cal system (Additional file 1, tab V). Over the course of 24
months (January 2007 through January 2009), we had 10
patient samples with positive PCP screens, nine on the
Syva EMIT assay and only one on the Biosite Triage assay
system (Additional file 1, tab V). Urine samples from
these 10 patients were also analyzed by GC/MS, using a
protocol to definitively identify a wide range of clinically
important legal and illicit drugs [28]. Of these, only one
patient showed the definitive presence of PCP by GC/MS
(30 year old female); this positive screen occurred on the
Syva EMIT system. The one positive PCP screen on the
Biosite Triage assay in our sample occurred in a 48 year
old female, with GC/MS analysis showing apparently very
high urine concentrations of diphenhydramine, a medica-
tion reported to cause positives on the Biosite Triage PCP
assay at high urine concentrations (Additional file 1, tab
P). The eight patient samples (average age 23.6 years,
range 2–44 years old; 5 males, 3 females) that had a posi-
tive PCP screen on the Syva EMIT assay not accounted for
by the presence of PCP all showed apparently high urine
concentrations of dextromethorphan by GC/MS that
would be consistent with intentional or inadvertent over-
dose of dextromethorphan. One of these samples also
showed the presence of apparently high urine concentra-
tions of meperidine by GC/MS. Relative to PCP, dex-
tromethorphan (Tanimoto similarity = 0.565) and
meperidine (Tanimoto similarity = 0.538) have similarity
coefficients higher than some of the PCP metabolites
compared to their parent drug (Additional file 1, tab P).
The common misuse of dextromethorphan suggests that,
in medical settings where PCP use is uncommon, false
positives on some marketed PCP assays (e.g., Syva EMIT)
due to dextromethorphan can occur more frequently than
true positives. In these cases, PCP screening assays may
become more effective as 'dextromethorphan overdose
screens' than as PCP screens. However, it should be
pointed out that at least five of the currently marketedBMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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Variability in sensitivity of marketed PCP and tricyclic antidepressant screening immunoassays Figure 4
Variability in sensitivity of marketed PCP and tricyclic antidepressant screening immunoassays. The plotted cir-
cles indicate the concentration of compound that produces equivalent reaction to 25 ng/mL PCP or 1000 ng/mL desipramine 
(tricyclic antidepressant assays). The dashed lines bracket clinically or toxicologically relevant concentrations from studies in 
the published literature (see text of Results for detailed description). A) PCP assays. Marketed PCP assays have varying degrees 
of cross-reactivity with dextromethorphan, meperidine, thioridazine, and mesoridazine. The brackets for PCP correspond to 
urine concentrations observed in patients abusing PCP[54] B) TCA assays. Marketed TCA screening immunoassays have simi-
lar cross-reactivities to TCAs but variable cross-reactivity to carbamazepine, phenothiazines (such as prochlorperazine), and 
quetiapine. The marketed TCA assays include those approved for serum/plasma or urine samples.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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PCP immunoassays are reported to be insensitive to dex-
tromethorphan (Additional file 1, tab P; Figure 4A). The
Biosite Triage system used in some hospitals in our medi-
cal system is an example of this. This may explain why all
but one of the PCP screen positives we documented
occurred on the Syva EMIT system, for which only 12,000
ng/mL of dextromethorphan, a concentration easily
obtainable in patients taking dextromethorphan-contain-
ing medications in overdose [55,56] will trigger a screen
positive equal to 25 ng/mL PCP (Additional file 1, tab P).
It should be noted that our laboratory has, over the last
two years, analyzed many urine specimens where dex-
tromethorphan is detectable by GC/MS but the PCP
screen is negative, supporting that only high urine con-
centrations of dextromethorphan can cause a false posi-
tive PCP screen.
Tricyclic Antidepressant Assays
Currently marketed TCA screening immunoassays use
either desipramine or imipramine, or multiple TCAs, as
target compounds (Additional file 1, tab T). Our similar-
ity calculations indicate that screening for TCAs is a diffi-
cult challenge for an immunoassay. In particular, several
phenothiazines and other non-TCA drugs have a relatively
high structural similarity to desipramine (or other TCAs),
which may explain why some non-TCA compounds cross-
react well with TCA screening assays (Additional file 1, tab
R; Figure 4B) [57-61]. Examples of the Tanimoto similar-
ities of TCAs and other tricyclic compounds relative to
desipramine are: amitriptyline (0.600), carbamazepine
(0.460), chlorpromazine (0.630), cyclobenzaprine
(0.565), doxepin (0.529), nortriptyline (0.628), prochlo-
rperazine (0.630), and quetiapine (0.485) (Table 3).
An additional challenge for TCA screening assays is that
prescriptions for TCAs have declined markedly in the
United States in the last fifteen years as other medications
such as the selective serotonin reuptake inhibitors (SSRIs)
have assumed steadily increasing shares of the market for
treatment of depression, obsessive-compulsive disorder,
and other psychiatric conditions (Additional file 2, figures
S2-G,H) [62]. This is illustrated in Figure 5A which shows
the rank of TCAs, cyclobenzaprine, and quetiapine among
the top prescribed medications in the United States in the
time period from 1998 to 2007. In 2007 [29], only
amitriptyline (#70) ranked in the top 100 most prescribed
medications, likely due in part to the extensive use of
amitriptyline for treating chronic pain [63], whereas nine
non-TCA antidepressants rank in the top 100 most pre-
scribed medications (sertraline, #23; escitalopram, #26;
fluoxetine, #36; bupropion, #44; paroxetine, #49; venla-
faxine, #55; citalopram, #56; trazodone, #59, and duloxe-
tine, #79) (Additional file 1, tab S; Additional file 2,
figures S2-G,H). As shown in Figure 5A, cyclobenzaprine
was prescribed more often than amitriptyline in 2007,
and quetiapine has also been approaching amitriptyline
in total number of prescriptions. Meanwhile, prescrip-
tions for the TCAs desipramine, doxepin, imipramine,
and nortriptyline have steadily declined in the last decade
with desipramine no longer ranking in the top most pre-
Tricyclic antidepressant assays Figure 5
Tricyclic antidepressant assays. A) Rank of tricyclic anti-
depressants, cyclobenzaprine, and quetiapine by total 
number of prescriptions in the United States in the time 
period from 1998–2007. TCAs are indicated by closed sym-
bols, while the non-TCAs (cyclobenzaprine and quetiapine) 
are designated by open circles and squares, respectively. 
Whereas prescriptions for amitriptyline have remained rela-
tively constant in the last decade, prescriptions for other 
TCAs are steadily declining, with desipramine no longer 
ranking in the top 400 most prescribed drugs. Cyclobenz-
aprine is now prescribed more frequently than amitriptyline 
in the United States. B) Drugs most likely accounting for pos-
itive TCAs immunoassay screens in our medical center sam-
ple. Of 124 positive TCA screens (see Additional file 1, tab U 
for details), the most likely causes were sorted into five cate-
gories: cyclobenzaprine, amitripytline +/- nortriptyline, other 
TCAs (e.g. doxepine, imipramine, and their metabolites), 
phenothiazines, and other drugs (e.g., carbamazepine and 
quetiapine).BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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scribed medications (Figure 5A, Additional file 1, tab S).
Prescriptions for phenothiazines have also declined dra-
matically over the last decade in the United States, with
'atypical' antipsychotics increasing significantly in clinical
use (Additional file 2, figures S2-H,I). This decline in use
of phenothiazines means they will likely account for
increasingly fewer false positives on TCA screening assays.
In our own medical system, we use two different assay
methods for TCA screening (Biosite Triage® and Syva Emit®
serum tox™). Over the course of 24 months (January 2007
through January 2009), we performed GC/MS analysis for
the broad detection of drugs and drug metabolites on all
samples that returned a positive screening result for TCA
assays (109 on Triage and 15 on Syva) to determine the
most likely cause of the positive result (Additional file 1,
tab U). As shown in Figure 5B, 70% of the positive results
were accounted for by the presence of amitriptyline
(28.2%) or cyclobenzaprine (41.9%), a centrally acting
muscle relaxant that differs from amitriptyline by the pres-
ence of one double bond [64]. Other TCAs accounted for
10.5% (1 imipramine and 10 doxepin cases) of the posi-
tive screens while two phenothiazines (chlorpromazine
and prochlorperazine) accounted for only 3.2% of the
positive screens. Thus, TCAs only accounted for 38.7% of
the most likely causes for the positive screening results in
our study. The remaining positive screens (16.0% of the
total) included patients whose urine showed high concen-
trations of venlafaxine (n = 2), carbamazepine (n = 2),
topiramate (n = 1), or quetiapine (n = 1). The frequency
of drugs most likely causing positive TCA screens in our
sample fits well with the overall prescription trends in the
United States (Figure 5A; Additional file 1, tab S) and the
known cross-reactivities of the Biosite Triage and Syva
EMIT assay systems. For example, the package insert for
the Triage assay states that a cyclobenzaprine urine con-
centration of only 2000 ng/mL will produce cross-reactiv-
ity equal to 1000 ng/mL TCAs (Additional file 1, tab R).
Given the current widespread use of cyclobenzaprine in
the United States (Figure 5A) [29,64], it is not surprising
to encounter false positive TCA screening assay results due
to the presence of this drug. The increasing use of
cyclobenzaprine and quetiapine will likely result in more
and more TCA positive screens resulting from these com-
pounds [17-19,59,65], especially combined with increas-
ing reports of intentional misuse and overdoses with
quetiapine [66-68].
Previous studies have shown cross-reactivity of quetiapine
(parent drug) with marketed TCA assays but did not look
at quetiapine metabolites [17-19,59,65]. We therefore
tested the Syva EMIT and Biosite Triage TCA screening
assays with drug-free serum (Syva) or urine (Biosite)
spiked with pure reference standards of each of three
quetiapine metabolites (DBTP, quetiapine S-oxide, 7-
hydroxyquetiapine) or quetiapine itself. None of these
four compounds, even at very high concentrations, cross-
reacted with the Biosite assay. We did find, however, that
cross-reactivity equal to 1000 ng/mL desipramine in the
Syva assay was produced by 100,000 ng/mL quetiapine,
50,000 ng/mL DBTP, or 200,000 ng/mL quetiapine S-
oxide. Although to our knowledge there is no published
data on serum or urine concentrations of quetapine
metabolites following quetiapine overdose, our data sug-
gest that quetiapine metabolites may contribute to cross-
reactivity with some TCA screening immunoassays.
DOA/Tox Screening Assays to Address Limitations of 
Standard Assays
As we have seen, several broad-specificity DOA/Tox
immunoassays may fail to detect all clinically important
members of a class of drugs (Table 1). To address this
issue, manufacturers have developed and marketed assays
for buprenorphine, heroin metabolite/6-AM, MDMA, and
oxycodone (Additional file 1, tabs D, H, J, and O). The
currently marketed assays for buprenorphine and oxyco-
done are reported to be highly specific for only these drugs
and their main metabolites (i.e., buprenophine glucuro-
nide and oxymorphone, respectively) [69]. One possible
limitation of the oxycodone assay is that it will not distin-
guish between the use of either oxycodone and oxymor-
phone. The only currently marketed heroin metabolite
immunoassay cross-reacts well with heroin and weakly
with structurally related opiates (hydromorphine, mor-
phine) (Additional file 1, tab H). The only currently mar-
keted MDMA assay cross-reacts well with a number of
designer amphetamines that are related structurally, e.g,
MDA (Tanimoto similarity to MDMA = 0.889) and MDEA
(0.850) but essentially does not cross-react with the less
similar d-amphetamine (0.361) or d-methamphetamine
(0.457) (Additional file 1, tab J).
Discussion
DOA/Tox screening immunoassays are widely used in
emergency medicine [5,7,10]. These assays are also used
by substance abuse treatment centers, chronic pain clinics,
and psychiatric units, in addition to employee and com-
petitive athlete drug screening programs [5,10]. The mul-
tiple uses of DOA/Tox screening tests probably provides
substantial inertia to attempts to alter assay design and
performance, as changes in assay design and detection
cutoffs could have wide-ranging impacts. The most com-
mon set of DOA/Tox screening assays (e.g., ampheta-
mines, barbiturates, benzodiazepines, cocaine
metabolite, opiates, and PCP), and their antigenic targets,
have remained remarkably similar across the last four dec-
ades.BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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As we have shown, false negatives for DOA/Tox screening
assays aimed at drug classes can occur with drugs that
became widely used in clinical practice in the United
States after the 1970s and which have relatively low struc-
tural similarity to the classic antigenic targets of their asso-
ciated immunoassays. For benzodiazepines, this includes
alprazolam, clobazam, clonazepam, and lorazepam,
while for opiates this includes buprenorphine, oxyco-
done, and oxymorphone. A few marketed immunoassays
(e.g., Biosite Triage) have attempted to broaden specificity
by using antibodies raised against multiple antigenic tar-
gets. The potential disadvantage of this approach is
reduced specificity and increased false positives. Also, any
alteration of these immunoassays has implications for
workplace and athlete testing, leading to pressure to keep
assay performance stable across many years of testing.
Many marketed DOA/Tox screening immunoassays have
documented cross-reactive drugs that can produce false
positives. In the medical setting, false positives can lead to
incorrect diagnoses and treatment. One way to limit false
positives is to use higher concentration cutoffs for deter-
mining what constitutes a positive screening result,
although this has the trade-off of reducing sensitivity. This
strategy is common in workplace DOA testing where cut-
off concentrations for a variety of DOA screening tests are
often higher than cutoffs used in the medical setting, so as
to limit false positives that require costly and time-con-
suming confirmatory testing [7,10]. For example, using
higher cutoffs helps reduce the issue of poppy seed inges-
tion causing a positive opiate screen [70] or passive mari-
juana inhalation resulting in a tetrahydrocannabinol
positive screen [71].
We demonstrated that PCP and TCA screening assays are
prone to false positives by common drugs that may be
taken in overdose, either in suicide attempts or for psy-
chotropic effects (e.g., dextromethorphan, meperidine).
In our own medical center study, there were more false
positives than true positives for both PCP and TCA screen-
ing assays applied to a clinical sample that included many
ED patients. This brings into question the utility of these
particular tests in settings where use/abuse of the target
drug(s) is uncommon.
One application of our Tanimoto similarity assessment
using the MDL keys would be to identify compounds that
have a high likelihood of cross-reacting with marketed
immunoassays. The 2D similarity method can readily
screen very large databases of many thousands of drugs
(including herbal products) and their metabolites. Com-
pounds with high Tanimoto similarity to the immu-
noassay antigenic target(s) can then be prioritized for
testing for cross-reactivity. This approach would provide a
more systematic approach to cross-reactivity testing and
may identify previously unknown clinically important
cross-reactive drug or drug metabolites more quickly,
leading to an increased recognition of potential cross-
reactivity by clinicians.
The steady increase in prescription and over-the-counter
medications available clinically presents a difficult chal-
lenge for future DOA/Tox immunoassay design. Some
newer therapeutic classes of drugs that are often taken in
overdose (e.g., atypical antipsychotics, SSRI antidepres-
sants) are actually not that closely related to one another
(see Additional file 1, tabs W and X). This is a contrast to
older drug classes (e.g., barbiturates, benzodiazepines,
and TCAs), where there is significant structural similarity
between all drugs within the class. The clinical implica-
tion of this is that it would be difficult to design an 'SSRI
overdose screen' or 'atypical antipsychotic overdose
screen' with standard immunoassay technology. It also
suggests that development of DOA/Tox immunoassays
has not kept pace with the development of new drugs rel-
evant to the ED community or with changes in patterns of
abuse of illicit and prescription drugs.
The analytical methods currently used mainly for DOA/
Tox confirmatory testing, such as GC/MS and liquid chro-
matography/tandem mass spectrometry (LC/MS/MS), can
specifically identify (and in some cases quantitate) drugs
and their metabolites. This technology, however, is tech-
nically demanding, labor-intensive, expensive compared
to immunoassays, and usually available only at reference
laboratories or in clinical laboratories associated with
larger medical centers [7]. A future goal would be to
develop and adapt GC/MS, LC/MS/MS, or a novel tech-
nology in a manner to be more widely accessible clini-
cally, so as to provide detailed drug exposure data with a
rapid turnaround time, allowing ED physicians to make
more specific diagnoses and treatment plans. A scientifi-
cally similar challenge is in emerging technology to
develop portable yet analytically robust sensors for chem-
ical warfare agents or environmental pollutants [72], and
there may be opportunities to develop clinical applica-
tions using related technology.
An important limitation of the 2D similarity approach
used in our study is that this cannot account for the com-
plex three-dimensional (3D) molecular interactions that
mediate antibody-antigen binding as occurs in immu-
noassays. To our knowledge, a 3D structure of an anti-
body used in a marketed DOA/Tox screening
immunoassay bound to its antigenic target has not been
reported, although there has been structural determina-
tion of several other antibodies being evaluated as novel
antidotes to DOA overdose (e.g., PCP [73] and cocaine
[74,75]), in which the antibody interacts with all portions
of the target molecule. For DOA/Tox screening immu-
noassays where similar antibody-drug interactions apply,
whole molecule similarity measures (as used in our study)BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
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seem appropriate for prediction; however, this may not
always be the case. A crystal structure of morphine bound
to a monoclonal antibody showed that the antibody inter-
acted with the more hydrophobic portion of morphine,
while the hydrophilic half was mostly solvent exposed
[76]. For target compounds like morphine, similarity
searching using substructures may therefore be worth
evaluating, although depending on the size of the mole-
cule, complexity, and novelty this may yield many more
molecules predicted as positives.
Conclusion
A combination of computational molecular similarity
and historical data analysis of the number of prescriptions
for drugs per year highlights some of the challenges in use
of routine DOA/Tox screening immunoassays for patient
management in emergency medicine. Although several
immunoassays do not currently yield high numbers of
false positives, others do and these can be simply
explained by some degree of structural similarity with the
immunoassay antigen. Additional DOA/Tox immu-
noassays for some therapeutic drug classes (e.g., benzodi-
azepines, opiates) possess high levels of false negatives
resulting from newer drugs which may have compara-
tively lower structural similarity with the immunoassay
antigenic target. ED physicians should therefore be aware
of substantial variability in different marketed assays with
respect to cross-reactivity of drugs, metabolites, and natu-
ral products. There is a current need for improved immu-
noassays or novel more specific technologies and closer
tracking of prescribing trends for drugs likely to cross-react
with DOA/Tox immunoassays.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MDK conceived of the study and structured the data. MDK
and SE drafted the manuscript. AFP participated in the
planning of the study, interpretation of data, and the his-
torical data analysis. MGS and SG performed and ana-
lyzed the laboratory studies involving immunoassays and
GC/MS. SE and MI performed the computational analy-
ses. All authors participated in editing and revising the
manuscript and approved the final version.
Additional material
Acknowledgements
The authors thank Darla Lower and Jackie Rymer for technical assistance, 
and Melissa Ratajeski and Ahlam Saleh (reference librarians, University of 
Pittsburgh Health Sciences Library System) for help in locating published 
data on drug prescriptions in the United States. SE gratefully acknowledges 
Accelrys, Inc. (San Diego, CA) for making Discovery Studio available. This 
research was supported by National Institutes of Health grant K08-
GM074238 to MDK.
References
1. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG,
Stricker BH: Hospitalisations and emergency department vis-
its due to drug-drug interactions: a literature review.  Pharma-
coepidemiol Drug Saf 2007, 16:641-651.
2. D'Onofrio G, Becker B, Woolard RH: The impact of alcohol,
tobacco, and other drug use and abuse in the emergency
department.  Emerg Med Clin North Am 2006, 24:925-967.
3. Wu AHB, McKay C, Broussard LA, Hoffman RS, Kwong TC, Moyer
TP, Otten EM, Welch SL, Wax P: National Academy of Clinical
Biochemistry laboratory medicine practice guidelines: rec-
ommendations for the use of laboratory tests to support poi-
soned patients who present to the emergency department.
Clin Chem 2003, 49:357-379.
4. Phillips DP, Barker GE, Eguchi MM: A steep increase in the
domestic fatal medication errors with use of alcohol and/or
street drugs.  Arch Intern Med 2008, 168:1561-1566.
5. Hammett-Stabler CA, Pesce AJ, Cannon DJ: Urine drug screening
in the medical setting.  Clin Chim Acta 2002, 315:125-135.
6. Kricka LJ: Principles of immunochemical techniques.  In Tietz
textbook of clinical chemistry and molecular diagnostics 4th edition. Edited
by: Burtis CA, Ashwood ER, Bruns DE. St. Louis, MO: Elsevier Saun-
ders; 2006:219-243. 
7. Porter WH: Clinical toxicology.  In Tietz textbook of clinical chemis-
try and molecular diagnostics Edited by: Burtis CA, Ashwood ER, Bruns
DE. St. Louis, MO: Elsevier Saunders; 2006:1287-1369. 
8. Mulé SJ, Bastos ML, Jukofsky D: Evaluation of immunoassay
methods for detection, in urine, of drugs subject to abuse.
Clin Chem 1974, 20:243-248.
9. Spector S, Flynn EJ: Barbiturates: radioimmunoassay.  Science
1971, 174:1036-1038.
10. Moeller KE, Lee KC, Kissack JC: Urine drug screening: practical
guide for clinicians.  Mayo Clin Proc 2008, 83:66-76.
11. Kricka LJ: Interferences in immunoassays – still a threat.  Clin
Chem 2000, 46:1037-1038.
12. Powers DM, Boyd JC, Glick MR: Interference testing in clinical
chemistry (EP7-A).  Villanova, PA: NCCLS; 1986. 
13. Baden LR, Horowitz G, Jacoby H, Eliopoulos GM: Quinolones and
false-positive urine screening for opiates by immunoassay
technology.  JAMA 2001, 286:3115-3119.
14. Bond GR, Steele PE, Uges DR: Massive venlafaxine overdose
resulted in a false positive Abbott AxSYM urine immu-
noassay for phencyclidine.  J Toxicol Clin Toxicol 2003,
41:999-1002.
15. Santos PM, López-García PN, J S, Fernández AS, Sádaba B, Vidal JP:
False positive phencyclidine results caused by venlafaxine.
Am J Psychiatry 2007, 164:349.
16. Sena SF, Kazimi S, Wu AH: False-positive phencyclidine immu-
noassay results caused by venlafaxine and O-desmethylven-
lafaxine.  Clin Chem 2002, 48:676-677.
Additional file 1
Similarity data and tricylic antidepressant/phencyclidine assay data. 
Spreadsheet with multiple tables contains data on similarity analyses, 
marketed assays, most prescribed medications, and cross-reactivity studies 
for phencyclidine and tricyclic antidepressant assays.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
227X-9-5-S1.xls]
Additional file 2
Historical trends in prescription drug usage in the United States that 
can impact drug of abuse testing. Data on trends in prescription drugs 
usage is presented by classes of drugs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
227X-9-5-S2.pdf]BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
Page 17 of 18
(page number not for citation purposes)
17. Caravati EM, Juenke JM, Crouch BI, Anderson KT: Quetiapine
cross-reactivity with plasma tricyclic antidepressant immu-
noassays.  Ann Pharmacother 2005, 39:1446-1449.
18. Henrickson RG, Morocco AP: Quetiapine cross-reactivity
among three tricyclic antidepressant immunoassays.  J Toxicol
Clin Toxicol 2003, 41:105-108.
19. Sloan KL, Haver VM, Saxon AJ: Quetiapine and false-positive
urine drug testing for tricyclic antidepressants.  Am J Psychiatry
2000, 157:148-149.
20. Bender A, Glen RC: Molecular similarity: a key technique in
molecular informatics.  Org Biomol Chem 2004, 2:3204-3218.
21. Willett P: Similarity-based approaches to virtual screening.
Biochem Soc Trans 2003, 31:603-606.
22. Ekins S, Mestres J, Testa B: In silico pharmacology for drug dis-
covery: applications to targets and beyond.  Br J Pharmacol
2007, 152:21-37.
23. Reddy AS, Pati SP, Kumar PP, Pradeep HN, Sastry GN: Virtual
screening in drug discovery – a computational perspective.
Curr Protein Pept Sci 2007, 8:329-351.
24. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffen-
hauer A: Comparison of topological descriptors for similarity-
based virtual screening using multiple bioactive reference
structures.  Org Biomol Chem 2004, 2:3256-3266.
25. Krasowski MD, Siam MG, Iyer M, Ekins S: Molecular similarity
methods for predicting cross-reactivity With therapeutic
drug monitoring immunoassays.  Ther Drug Monit 2009 in press.
26. Krasowski MD, Siam MG, Iyer M, Pizon AF, Giannoutsos S, Ekins S:
Chemoinformatic methods for predicting interference in
drug of abuse/toxicology immunoassays.  Clin Chem   2009,
55:1203-1213.
27. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL: Glo-
bal mapping of pharmacological space.  Nat Biotechnol 2006,
24:805-815.
28. Pizon AF, Schwartz AR, Shum LM, Rittenberger JC, Lower DR, Gian-
noutsos S, Virji MA, Krasowski MD: Toxicology laboratory anal-
ysis and human exposure to p-chloroaniline.  Clin Toxicol (Phila)
2009, 47(2):132-136.
29. Red Book.  Montvale, NJ: Thomson Healthcare; 2008. 
30. Wolff K, Winstock AR: Ketamine: from medicine to misuse.
CNS Drugs 2006, 20:199-218.
31. Cody JT, Valtier S, Nelson SL: Amphetamine excretion profile
following multidose adminstration of mixed salt ampheta-
mine preparation.  J Anal Toxicol 2004, 28:563-574.
32. Kim I, Oyler JM, Moolchan ET, Cone EJ, Huestis MA: Urinary phar-
macokinetics of methamphetamine and its metabolite,
amphetamine following controlled oral administration to
humans.  Ther Drug Monit 2004, 26:664-672.
33. Liu RH, Liu H-C, Lin D-L: Distribution of methylenedioxymeth-
amphetamine (MDMA) and methylenedioxyamphetamine
(MDA) in postmortem and antemortem specimens.  J Anal
Toxicol 2006, 30:545-550.
34. Levine B, Caplan YH, Dixon AM: A fatality involving phenter-
mine.  J Forensic Sci 1984, 29(4):1242-1245.
35. Katz RL: Sedatives and tranquilizers.  New Engl J Med 1972,
286:757-760.
36. Bastiani RJ, Phillips RC, Schneider RS, Ullman EF: Homogenous
immunochemical drug assays.  Am J Med Technol 1973,
39:211-216.
37. Peskar B, Spector S: Quantitative determination of diazepam
in blood by immunoassay.  J Pharmacol Exp Ther 1973,
186:167-172.
38. Kanto J, Sellman R, Haataja M, Hurme P: Plasma and urine concen-
trations of diazepam and its metabolites in children, adults
and in diazepam-intoxicated patients.  Int J Clin Pharmacol Biop-
harm 1978, 16(6):258-264.
39. Kaplan SA, Alexander K, Jack ML, Puglisi CV, de Silva JAF, Lee TL,
Weinfeld RE: Pharmacokinetic profiles of clonazepam in dog
and humans and flunitrazepam in dog.  J Pharm Sci 1974,
63:527-532.
40. Negrusz A, Bowen AM, Moore CM, Dowd SM, Strong MJ, Janicak PG:
Elimination of 7-aminoclonazepam in urine after a single
dose of clonazepam.  Anal Bioanal Chem 2003, 376:1198-1204.
41. Greenblatt DJ, Joyce TH, Comer WH, Knowles JA, Shader RI, Kyria-
kopoulos AA, MacLaughlin DS, Ruelius HW: Clinical pharmacoki-
netics of lorazepam. II. Intramuscular injection.  Clin Pharmacol
Ther 1977, 21:222-230.
42. Greenblatt DJ, Schillings RT, Kyriakopoulos AA, Shader RI, Sisenwine
SF, Knowles JA, Ruelius HW: Clinical pharmacokinetics of
lorazepam. I. Absorption and disposition of oral 14C-
lorazepam.  Clin Pharmacol Ther 1976, 20:329-341.
43. Borrey D, Meyer E, Duchateau L, Lambert W, Van Peteghem C, De
Leenheer A: Enzymatic hydrolysis improves the sensitivity of
Emit screening for urinary benzodiazepines.  Clin Chem 2002,
48:2047-2049.
44. Klette KL, Wiegand RF, Horn CK, Stout PR, Magluilo J: Urine ben-
zodiazepine screening using Roche Online KIMS immu-
noassay with β-glucuronidase hydrolysis and confirmation by
gas chromatography-mass spectrometry.  J Anal Toxicol 2005,
29:193-200.
45. Huestis MA, Darwin WD, Shimomura E, Lalani SA, Trinidad DV,
Jenkins AJ, Cone EJ, Jacobs AJ, Smith ML, Paul BD: Cocaine and
metabolites urinary excretion after controlled smoked
administration.  J Anal Toxicol 2007, 31:462-468.
46. Harris DS, Everhart ET, Mendelson J, Jones RT: The pharmacology
of cocaethylene administration in humans following cocaine
and ethanol administration.  Drug Alcohol Depend 2003,
72:169-182.
47. Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone
for pain management.  Ann Pharmacother 2007, 41:1144-1152.
48. Compton WM, Volkow ND: Major increases in opioid analgesic
abuse in the United States: concerns and strategies.  Drug
Alcohol Depend 2006, 81:103-107.
49. Mayo Medical Laboratories, Urine Opiates   [http://www.may
omedicallaboratories.com/test-catalog/Clinical+and+Interpretive/
8473]
50. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW: Oxymor-
phone metabolism and urinary excretion in human, rat,
guinea pig, rabbit, and dog.  Drug Metab Dispos 1983, 11:446-450.
51. Pöyhiä R, Seppäla T, Olkkola KT, Kalso E: The pharmacokinetics
and metabolism of oxycodone after intramuscular and oral
administration to healthy subjects.  Br J Clin Pharmacol 1992,
33:617-621.
52. Smith ML, Shimomura ET, Summers J, Paul BD, Jenkins AJ, Darwin
WD, Cone EJ: Urinary excretion profiles for total morphine,
free morphine, and 6-acetylmorphine following smoked and
intravenous heroin.  J Anal Toxicol 2001, 25:504-514.
53. Thombs DL: A review of PCP abuse trends and perceptions.
Public Health Rep 1989, 104:325-328.
54. Cone EJ, Buchwald W, Yousnefnejad D: Simultaneous determina-
tion of phencyclidine and monohydroxylated metabolites in
urine of man by gas chromatography-mass fragmentography
with methane chemical ionization.  J Chromatogr 1981,
223:331-339.
55. Schwartz RH: Adolescent abuse of dextromethorphan.  Clin
Pediatr (Phila) 2005, 44:565-568.
56. Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson
IB: Dextromethorphan abuse in adolescence: an increasing
trend: 1999–2004.  Arch Pediatr Adolesc Med 2006, 160:1217-1222.
57. Dasgupta A, Wells A, Datta P: False-positive serum tricyclic anti-
depressant concentrations using fluorescence polarization
immunoassay due to the presence of hydroxyzine and ceti-
rizine.  Ther Drug Monit 2007, 29:134-139.
58. Meenan GM, Barlotta S, Lehrer M: Urinary tricyclic antidepres-
sant screening: comparison of results obtained with Abbott
FPIA reagents and Syva EIA reagents.  J Anal Toxicol 1990,
14:273-276.
59. Melanson SE, Lewandrowski EL, Griggs DA, Flood JG: Interpreting
tricyclic antidepressant measurements in urine in an emer-
gency department setting: comparison of two qualitative
point-of-care urine tricyclic antidepressant drug immu-
noassays with quantitative serum chromatographic analysis.
J Anal Toxicol 2007, 31:270-275.
60. Nebinger P, Koel M: Specificity data of the tricyclic antidepres-
sants assay by fluorescent polarization immunoassay.  J Anal
Toxicol 1990, 14:219-221.
61. Schwartz JG, Hurd IL, Carnahan JJ: Determination of tricyclic
antidepressants for ED analysis.  Am J Emerg Med 1994,
12:513-516.
62. Belmaker RH, Agam G: Major depressive disorder.  New Engl J
Med 2008, 358:55-68.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Emergency Medicine 2009, 9:5 http://www.biomedcentral.com/1471-227X/9/5
Page 18 of 18
(page number not for citation purposes)
63. Jann MW, Slade JH: Antidepressant agents for the treatment of
chronic pain and depression.  Pharmacotherapy 2007,
27:1571-1587.
64. Lofland JH, Szarlej D, Buttaro T, Shermock S, Jalalil S: Cyclobenz-
aprine hydrochloride is a commonly prescribed centrally
acting muscle relaxant, which is structurally similar to tricy-
clic antidepressants (TCAs), and differs from amitriptyline
by only one double bond.  Clin J Pain 2001, 17:103-104.
65. Van Hoey NM: Effect of cyclobenzaprine on tricyclic antide-
pressant assays.  Ann Pharmacother 2005, 39:1314-1317.
66. Hussain MZ, Waheed W, Hussain S: Intravenous quetiapine
abuse.  Am J Psychiatry 2005, 162:1755-1756.
67. Reeves RR, Brister JC: Additional evidence of the abuse poten-
tial of quetiapine.  South Med J 2007, 100:834-836.
68. Waters BM, Joshi KG: Intravenous quetiapine-cocaine use ("Q-
ball").  Am J Psychiatry 2007, 164:173-174.
69. Backer RC, Monforte JR, Poklis A: Evaluation of the DRI® Oxyco-
done immunoassay for the detection of oxycodone in urine.
J Anal Toxicol 2005, 29:675-677.
70. Fraser AD, Worth D: Experience with a urine opiate screening
and confirmation cutoff of 2000 ng/mL.  J Anal Toxicol 1999,
23:549-551.
71. Mørland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T:
Cannabinoids in blood and urine after passive inhalation of
Cannabis smoke.  J Forensic Sci 1985, 30(4):997-1002.
72. Arduini F, Amine A, Moscone D, Ricci F, Palleschi G: Fast, sensitive
and cost-effective detection of nerve agents in the gas phase
using a portable instrument and an electrochemical biosen-
sor.  Anal Bioanal Chem 2007, 388:1049-1057.
73. Lim K, Owens SM, Arnold L, Sacchettini JC, Linthicum DS: Crystal
structure of monoclonal 6B5 Fab complexed with phencycli-
dine.  J Biol Chem 1998, 273:28576-28582.
74. Larsen NA, Zhou B, Heine A, Wirsching P, Janda KD, Wilson IA:
Crystal structure of a cocaine-binding antibody.  J Mol Biol
2001, 311:9-15.
75. Pozharski E, Moulin A, Hewagama A, Shanafelt AB, Petsko GA, Ringe
D: Diversity in hapten recognition: structural study of an
anti-cocaine M82G2.  J Mol Biol 2005, 349:570-582.
76. Pozharski E, Wilson MA, Hewagama A, Shanafelt AB, Petsko G, Ringe
D: Anchoring a cationic ligand: the structure of the Fab frag-
ment of the anti-morphine antibody 9B1 and its complex
with morphine.  J Mol Biol 2004, 337:691-697.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-227X/9/5/prepub